文献速递治疗药物监测与药物基因组学药物相互作用

医院药物审查中实施药物基因组学检测的可行性研究

Implementation of pharmacogenetic testing in medication reviews in a hospital setting.
PubMed 文献 · Br J Clin Pharmacol · 2023-06-22

该研究纳入46例有多种慢性病且至少存在一个潜在基因-药物相互作用的住院患者,进行药物基因组学检测并尝试将结果用于药物审查。结果显示仅39.1%的患者在住院期间可获得检测结果用于审查,药师对42.9%的可干预基因-药物相互作用提出用药调整建议,医生接受率达90.5%。结论认为该策略有改善转诊前药物治疗的潜力,但物流流程需进一步优化。

要点

  • 药物基因组学检测结果在住院期间可用于药物审查的患者不足一半(39.1%)。
  • 药师对可干预基因-药物相互作用提出调整建议,医生接受率高达90.5%。
  • 最常见的基因-药物相互作用涉及美托洛尔、氯吡格雷和阿托伐他汀。

核心结论

  • 住院患者药物审查中实施药物基因组学检测具有改善转诊前药物治疗的潜力,但物流流程需进一步优化。

研究设计与样本

  • 研究纳入来自一个老年病房和一个心内科病房的46例患者,均患≥2种慢性病、规律用药≥5种且至少存在一个潜在基因-药物相互作用。

主要发现

  • 46例患者中仅18例(39.1%)在住院期间可获得药物基因组学检测结果用于药物审查,中位住院时间为4.7天(1.6-18.3)。
  • 共检测到49个基因-药物相互作用,药师对其中21个(42.9%)推荐了用药调整。
  • 医院医生接受了19条(90.5%)药师推荐。
  • 最常见的基因-药物相互作用涉及美托洛尔(CYP2D6基因型)、氯吡格雷(CYP2C19基因型)和阿托伐他汀(CYP3A4/5和SLCO1B1基因型)。

临床怎么用

  • 对于有多种慢性病且存在潜在基因-药物相互作用的住院患者,可考虑在药物审查中整合药物基因组学检测,但需关注检测周转时间对住院期间干预可行性的影响。

局限性

  • 检测结果仅在不足一半的患者住院期间可用,物流工作流程限制了该策略的即时应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To investigate whether it is feasible to perform pharmacogenetic testing and implement the test results as part of medication reviews during hospitalization of multimorbid patients. METHODS: Patients with ≥2 chronic conditions and ≥5 regular drugs with at least one potential gene-drug interaction (GDI) were included from one geriatric and one cardiology ward for pharmacogenetic testing. After inclusion by the study pharmacist, blood samples were collected and shipped to the laboratory for analysis. For patients still hospitalized at the time when the pharmacogenetic test results were available, the information was used in medication reviews. Recommendations from the pharmacist on actionable GDIs were communicated to the hospital physicians, who subsequently decided on potential immediate changes or forwarded suggestions in referrals to general practitioners. RESULTS: The pharmacogenetic test results were available for medication review in 18 of the 46 patients (39.1%), where median length of hospital stay was 4.7 days (1.6-18.3). The pharmacist recommended medication changes for 21 of 49 detected GDIs (42.9%). The hospital physicians accepted 19 (90.5%) of the recommendations. The most commonly detected GDIs involved metoprolol (CYP2D6 genotype), clopidogrel (CYP2C19 genotype) and atorvastatin (CYP3A4/5 and SLCOB1B1 genotype). CONCLUSIONS: The study shows that implementation of pharmacogenetic testing for medication review of hospitalized patients has the potential to improve drug treatment before being transferred to primary care. However, the logistics workflow needs to be further optimized, as test results were available during hospitalization for less than half of the patients included in the study.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hjemås BJ, Bøvre K, Bjerknes K, et al. Implementation of pharmacogenetic testing in medication reviews in a hospital setting. Br J Clin Pharmacol. 2023. PMID: 37277227. doi:10.1111/bcp.15815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。